HLN

Haleon Plc ADR (HLN) | Rumor.io

Haleon

HLN

Attention (50-day avg)0%

Attention rank (50-day avg)#3,743

Bullish sentiment (50-day avg)0%

Price to earnings ratio19.3

Market capitalization40.3B

Earnings per share0.48

Dividend yield (TTM)—

Revenue (annual)11B

Net income (annual)1.7B

Social

What share of all stock conversation is about HLN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0.01% +0

Jun 7

The stocks $INFQ, $HLN, and $GT may rise.
A blogger with accurate analysis and predictions is recommended to follow, reportedly making $8,000 every two weeks.
No specific information about Haleon plc is mentioned in the provided posts.

Generated by AI

Sentiment

Of the messages about HLN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0%	96.74% +0.76
Bearish	—	—	100%	3.26% -0.76

Jun 7

Haleon plc ($HLN) is one of several stocks that may rise, according to a blogger with accurate analysis and predictions.
This blogger has made a lot of money following their analysis and predictions, suggesting a potential high return on investment for $HLN.
$HLN is mentioned alongside other stocks as a potential opportunity for investors who are not already making significant profits.

Generated by AI

Topics

Of the messages about HLN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	0.07%
Technical Analysis	—	—	100%	1.16%
Analysts	—	—	0%	49.39%
Controversies	—	—	0%	0.01%
Earnings	—	—	0%	0%
Macro	—	—	0%	49.37%

Announcements· Jul 18

Haleon (HLN) begins trading on the London Stock Exchange (LSE) after being spun off from GlaxoSmithKline (GSK), with a stock valuation of around £31bn.
The spin-off is the largest consumer health business in the world, containing well-known brands such as Advil and Sensodyne, and has an enterprise value of ~£40bn.
Haleon's shares started trading at GBP£3.30/share, implying an EV of ~£40bn, or ~16.9x EBITDA, below Unilever's £50bn / 21x offer in January.

Controversies· Aug 11

Haleon (HLN) is not a party to the US litigation focused on Zantac, despite market reaction indicating otherwise.
The company has indemnification obligations to GSK and Pfizer, but analysts consider its involvement in the Zantac litigation limited.
Haleon's substantial debt and historical ties to GSK may be contributing to its undervaluation and market volatility.

Generated by AI

Community

Of the messages about HLN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	4.38%
Newcomers	—	—	100%	95.62%

Jun 7

New investors are excited about the potential for Haleon plc to rise in value, considering it among stocks that may increase.
Following a blogger who makes $8,000 every two weeks has led to successful investments for some, including a detailed explanation of their analysis and predictions.
The blogger's predictions have been accurate, allowing them to make a significant amount of money, and their analysis is highly recommended to those looking to invest.

Generated by AI

Haleon PLC (LSE:HLN, NYSE:HLN), the consumer healthcare group, is expected to reduce its 2026 organic sales growth guidance after UBS forecast a subdued third quarter and limited visibility over the cough and cold season. UBS expects Haleon to report organic sales growth of 3.1% for the three...

5d agoYahoo Finance UK

Haleon is Buying Better Shelf Space, Can the Visibility Help it Against Procter & Gamble and Colgate-Palmolive?

Haleon plc (NYSE:HLN) is trying to win the US consumer-health market one shelf at a time. The Sensodyne and Advil owner has secured more prominent positions at Walmart Inc. (NYSE:WMT), Target Corporation (NYSE:TGT), and other major retailers by offering improved commercial terms, including lower prices, stronger promotions, new products, and exclusivity. READ ALSO: Keurig Dr […]

5d agoYahoo Finance

Deutsche Bank stays bearish on Haleon as growth headwinds mount

Deutsche Bank has reiterated its 'sell' rating on Haleon PLC (LSE:HLN, NYSE:HLN), warning that the consumer health group faces persistent pressure on growth even as it heads into the cold and flu season. The broker kept a 320p price target on the FTSE 100 company, whose brands include...

7d agoYahoo Finance

Haleon Turns to Weight-Loss Drug Users for its Next U.S. Growth Opportunity

Haleon plc (NYSE:HLN) is finding a new growth opportunity in the expanding U.S. population using GLP-1 weight-loss drugs such as Wegovy and Zepbound. According to Reuters, the company has been placing products that can address GLP-1-related side effects in both its normal store locations and dedicated GLP-1 sections at CVS. That strategy has produced an […]

8d agoYahoo Finance

Also Discussed

Investors talking about HLN also mention

#	Name	Attention
1	Black Diamond Therapeutics, Inc.BDTX	0%new
2	Independence Realty Trust Inc.IRT	0%new
3	SongbirdSGB	0.01%+0.01
4	FlareFLR	0.03%-0.03
5	Corebridge Financial Inc.CRBG	0%0
6	W. P. Carey Inc.WPC	0%+0
7	Kenvue Inc.KVUE	0%0
8	Crescent Energy Company Class A Common StockCRGY	0%0
9	Innovator Equity Managed Floor ETFSFLR	0%new
10	Fluor CorporationFLR	0%0

Haleon Plc ADR

Healthcare
Drug Manufacturers - Specialty & Generic

Haleon Plc ADR is an American depositary receipt representing Haleon plc, a consumer healthcare company headquartered in Weybridge, United Kingdom. Haleon develops, manufactures, and markets a broad range of self-care products focused on everyday health needs, including oral health, pain relief, respiratory care, digestive health, and vitamins and supplements. Its portfolio serves consumers seeking non-prescription solutions for routine wellness and symptom management across North America, Europe, Latin America, and Asia Pacific. The company operates in the healthcare sector through well-known consumer brands that are distributed through pharmacies, grocery channels, mass retailers, and other consumer-facing outlets. Haleon Plc ADR provides U.S. investors access to a globally diversified consumer health business with exposure to demand for essential, repeat-purchase healthcare products.

Website

Location

The Heights

Weybridge, KT13 0NY

United Kingdom

Social

What share of all stock conversation is about HLN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0.01% +0

Jun 7

The stocks $INFQ, $HLN, and $GT may rise.
A blogger with accurate analysis and predictions is recommended to follow, reportedly making $8,000 every two weeks.
No specific information about Haleon plc is mentioned in the provided posts.

Generated by AI

Sentiment

Of the messages about HLN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0%	96.74% +0.76
Bearish	—	—	100%	3.26% -0.76

Jun 7

Haleon plc ($HLN) is one of several stocks that may rise, according to a blogger with accurate analysis and predictions.
This blogger has made a lot of money following their analysis and predictions, suggesting a potential high return on investment for $HLN.
$HLN is mentioned alongside other stocks as a potential opportunity for investors who are not already making significant profits.

Generated by AI

Topics

Of the messages about HLN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	0.07%
Technical Analysis	—	—	100%	1.16%
Analysts	—	—	0%	49.39%
Controversies	—	—	0%	0.01%
Earnings	—	—	0%	0%
Macro	—	—	0%	49.37%

Announcements· Jul 18

Haleon (HLN) begins trading on the London Stock Exchange (LSE) after being spun off from GlaxoSmithKline (GSK), with a stock valuation of around £31bn.
The spin-off is the largest consumer health business in the world, containing well-known brands such as Advil and Sensodyne, and has an enterprise value of ~£40bn.
Haleon's shares started trading at GBP£3.30/share, implying an EV of ~£40bn, or ~16.9x EBITDA, below Unilever's £50bn / 21x offer in January.

Controversies· Aug 11

Haleon (HLN) is not a party to the US litigation focused on Zantac, despite market reaction indicating otherwise.
The company has indemnification obligations to GSK and Pfizer, but analysts consider its involvement in the Zantac litigation limited.
Haleon's substantial debt and historical ties to GSK may be contributing to its undervaluation and market volatility.

Generated by AI

Community

Of the messages about HLN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	4.38%
Newcomers	—	—	100%	95.62%

Jun 7

New investors are excited about the potential for Haleon plc to rise in value, considering it among stocks that may increase.
Following a blogger who makes $8,000 every two weeks has led to successful investments for some, including a detailed explanation of their analysis and predictions.
The blogger's predictions have been accurate, allowing them to make a significant amount of money, and their analysis is highly recommended to those looking to invest.

Generated by AI

Haleon

Social

Jun 7

Sentiment

Jun 7

Topics

Announcements· Jul 18

Controversies· Aug 11

Community

Jun 7

News

J.P. Morgan flags negative catalyst at Haleon on weak sales momentum

JPMorgan cuts Haleon stock price target on growth concerns

Haleon tipped to cut sales growth guidance as cough and cold season clouds outlook

Haleon is Buying Better Shelf Space, Can the Visibility Help it Against Procter & Gamble and Colgate-Palmolive?

Deutsche Bank stays bearish on Haleon as growth headwinds mount

Haleon Turns to Weight-Loss Drug Users for its Next U.S. Growth Opportunity

Also Discussed

Haleon Plc ADR

Company Information

Location

News

J.P. Morgan flags negative catalyst at Haleon on weak sales momentum

JPMorgan cuts Haleon stock price target on growth concerns

Haleon tipped to cut sales growth guidance as cough and cold season clouds outlook

Haleon is Buying Better Shelf Space, Can the Visibility Help it Against Procter & Gamble and Colgate-Palmolive?

Deutsche Bank stays bearish on Haleon as growth headwinds mount

Haleon Turns to Weight-Loss Drug Users for its Next U.S. Growth Opportunity

Also Discussed

Social

Jun 7

Sentiment

Jun 7

Topics

Announcements· Jul 18

Controversies· Aug 11

Community

Jun 7